{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:16:35Z","timestamp":1777500995289,"version":"3.51.4"},"reference-count":47,"publisher":"Becaris Publishing Limited","funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            The budgetary consequences of increasing dronedarone utilization for treatment of atrial fibrillation were evaluated from a US payer perspective.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A budget impact model over a 5-year time horizon was developed, including drug-related costs and risks for long-term clinical outcomes (LTCOs). Treatments included antiarrhythmic drugs (AADs; dronedarone, amiodarone, sotalol, propafenone, dofetilide, flecainide), rate control medications, and ablation. Direct comparisons and temporal and non-temporal combination scenarios investigating treatment order were analyzed as costs per patient per month (PPPM).\n            <jats:bold>Results:<\/jats:bold>\n            By projected year 5, costs PPPM for dronedarone versus other AADs decreased by $37.69 due to fewer LTCOs, treatment with dronedarone versus ablation or rate control medications\u00a0+\u00a0ablation resulted in cost savings ($359.94 and $370.54, respectively), and AADs placed before ablation decreased PPPM costs by $242 compared with ablation before AADs.\n            <jats:bold>Conclusion<\/jats:bold>\n            Increased dronedarone utilization demonstrated incremental cost reductions over time.\n          <\/jats:p>","DOI":"10.57264\/cer-2022-0196","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T12:22:05Z","timestamp":1678796525000},"source":"Crossref","is-referenced-by-count":3,"title":["A value-based budget impact model for dronedarone compared with other rhythm control strategies"],"prefix":"10.57264","author":[{"given":"Jennifer","family":"Ken-Opurum","sequence":"first","affiliation":[{"name":"Axtria Inc., Decision Science, Health Economics and Outcomes Research \/ Real-World Evidence, Berkley Heights, NJ 07922, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sesha SS","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Axtria Inc., Decision Science, Health Economics and Outcomes Research \/ Real-World Evidence, Berkley Heights, NJ 07922, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratyusha","family":"Vadagam","sequence":"additional","affiliation":[{"name":"Axtria Inc., Decision Science, Health Economics and Outcomes Research \/ Real-World Evidence, Berkley Heights, NJ 07922, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Faith","sequence":"additional","affiliation":[{"name":"Axtria Inc., Decision Science, Health Economics and Outcomes Research \/ Real-World Evidence, Berkley Heights, NJ 07922, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seojin","family":"Park","sequence":"additional","affiliation":[{"name":"Sanofi US, US General Medicines, Bridgewater, NJ\u00a008807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Charland","sequence":"additional","affiliation":[{"name":"Sanofi US, US General Medicines, Bridgewater, NJ\u00a008807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Revel","sequence":"additional","affiliation":[{"name":"Sanofi US, US General Medicines, Bridgewater, NJ\u00a008807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Preblick","sequence":"additional","affiliation":[{"name":"Sanofi US, US General Medicines, Bridgewater, NJ\u00a008807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"e_1_3_4_3_2","unstructured":"Mayo Clinic. Atrial fibrillation. https:\/\/www.mayoclinic.org\/diseases-conditions\/atrial-fibrillation\/symptoms-causes\/syc-20350624 (Accessed 7 July 2021)."},{"issue":"5","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42(5), 373\u2013498 (2021).","journal-title":"Eur. Heart J."},{"issue":"8","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla S","year":"2013","unstructured":"Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am. J. Cardiol. 112(8), 1142\u20131147 (2013).","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1524-4733.2006.00124.x","article-title":"Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States","volume":"9","author":"Coyne KS","year":"2006","unstructured":"Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 9(5), 348\u2013356 (2006).","journal-title":"Value Health"},{"issue":"11","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip GYH","year":"2017","unstructured":"Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat. Rev. Cardiol. 14(11), 627\u2013628 (2017).","journal-title":"Nat. Rev. Cardiol."},{"issue":"14","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early Rhythm-Control Therapy in Patients with Atrial Fibrillation","volume":"383","author":"Kirchhof P","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N. Engl. J. Med. 383(14), 1305\u20131316 (2020).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_4_9_2","unstructured":"Mayo Clinic. Atrial fibrillation ablation. https:\/\/www.mayoclinic.org\/tests-procedures\/atrial-fibrillation-ablation\/about\/pac-20384969 (Accessed 24 March 2022)."},{"issue":"5","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/europace\/eux373","article-title":"Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP)","volume":"20","author":"Dan GA","year":"2018","unstructured":"Dan GA, Martinez-Rubio A, Agewall S Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace 20(5), 731\u2013732an (2018).","journal-title":"Europace"},{"issue":"11","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1540-8167.2008.01251.x","article-title":"Dronedarone: a new treatment for atrial fibrillation","volume":"19","author":"Laughlin JC","year":"2008","unstructured":"Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J. Cardiovasc. Electrophysiol. 19(11), 1220\u20131226 (2008).","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"7","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser SH","year":"2009","unstructured":"Hohnloser SH, Crijns HJ, Van Eickels M Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360(7), 668\u2013678 (2009).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_4_13_2","unstructured":"Drugs.com. Multaq. https:\/\/www.drugs.com\/pro\/multaq.html (Accessed 26 April 2021)."},{"key":"e_1_3_4_14_2","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation","volume":"9","author":"Valembois L","year":"2019","unstructured":"Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst. Rev. 9, CD005049 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/europace\/euq450","article-title":"Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation","volume":"13","author":"Freemantle N","year":"2011","unstructured":"Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13(3), 329\u2013345 (2011).","journal-title":"Europace"},{"key":"e_1_3_4_16_2","unstructured":"US Bureau of Labor Statistics. CPI Inflation Calculator. https:\/\/www.bls.gov\/data\/inflation_calculator.htm (Accessed 26 April 2021)."},{"issue":"4","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/CIRCEP.108.837294","article-title":"Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation","volume":"2","author":"Reynolds MR","year":"2009","unstructured":"Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ. Arrhythm Electrophysiol. 2(4), 362\u2013369 (2009).","journal-title":"Circ. Arrhythm Electrophysiol."},{"issue":"17","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/0002-9149(91)90326-G","article-title":"Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine","volume":"68","author":"Podrid PJ","year":"1991","unstructured":"Podrid PJ, Kowey PR, Frishman WH Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine. Am. J. Cardiol. 68(17), 1662\u20131667 (1991).","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3111\/13696998.2014.911185","article-title":"Cost-effectiveness of the convergent procedure and catheter ablation for non-paroxysmal atrial fibrillation","volume":"17","author":"Anderson LH","year":"2014","unstructured":"Anderson LH, Black EJ, Civello KC, Martinson MS, Kress DC. Cost-effectiveness of the convergent procedure and catheter ablation for non-paroxysmal atrial fibrillation. J. Med. Econ. 17(7), 481\u2013491 (2014).","journal-title":"J. Med. Econ."},{"issue":"3","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40273-013-0028-7","article-title":"Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation","volume":"31","author":"Bruggenjurgen B","year":"2013","unstructured":"Bruggenjurgen B, Kohler S, Ezzat N, Reinhold T, Willich SN. Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation. Pharmacoeconomics 31(3), 195\u2013213 (2013).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_4_21_2","unstructured":"Drugs.com. Multaq Prices Coupons and Patient Assistance Programs. https:\/\/www.drugs.com\/price-guide\/multaq (Accessed 19 October 2021)."},{"key":"e_1_3_4_22_2","unstructured":"Drugs.com. Amiodarone Prices Coupons and Patient Assistance Programs. https:\/\/www.drugs.com\/price-guide\/amiodarone (Accessed 19 October 2021)."},{"key":"e_1_3_4_23_2","unstructured":"Drugs.com. Sotalol Prices Coupons and Patient Assistance Programs. https:\/\/www.drugs.com\/price-guide\/sotalol (Accessed 19 October 2021)."},{"key":"e_1_3_4_24_2","unstructured":"Drugs.com. Flecainide Prices Coupons and Patient Assistance Programs. https:\/\/www.drugs.com\/price-guide\/flecainide (Accessed 19 October 2021)."},{"key":"e_1_3_4_25_2","unstructured":"Drugs.com. Propafenone Prices Coupons and Patient Assistance Programs. https:\/\/www.drugs.com\/price-guide\/propafenone (Accessed 19 October 2021)."},{"key":"e_1_3_4_26_2","unstructured":"Drugs.com. Dofetilide Prices Coupons and Patient Assistance Programs. https:\/\/www.drugs.com\/price-guide\/dofetilide (Accessed 19 October 2021)."},{"key":"e_1_3_4_27_2","unstructured":"Drugs.com. Dronedarone Dosage. https:\/\/www.drugs.com\/dosage\/dronedarone.html (Accessed 19 October 2021)."},{"key":"e_1_3_4_28_2","unstructured":"Drugs.com. Amiodarone Dosage. https:\/\/www.drugs.com\/dosage\/amiodarone.html (Accessed 19 October 2021)."},{"key":"e_1_3_4_29_2","unstructured":"Drugs.com. Sotalol Dosage. https:\/\/www.drugs.com\/dosage\/sotalol.html (Accessed 19 October 2021)."},{"key":"e_1_3_4_30_2","unstructured":"Drugs.com. Flecainide Dosage. https:\/\/www.drugs.com\/dosage\/flecainide.html (Accessed 19 October 2021)."},{"key":"e_1_3_4_31_2","unstructured":"Drugs.com. Propafenone Dosage. https:\/\/www.drugs.com\/dosage\/propafenone.html (Accessed 19 October 2021)."},{"key":"e_1_3_4_32_2","unstructured":"Centers for Medicare & Medicaid Services. License for Use of Current Procedural Terminology Fourth Edition (\u201cCPT \u00ae \u201d). https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/license-agreement?destination=\/medicare\/physician-fee-schedule\/search%3FY%3d0%26T%3d4%26HT%3d0%26CT%3d3%26H1%3d99214%26M%3d5 (Accessed 19 October 2021)."},{"key":"e_1_3_4_33_2","unstructured":"BETAPACE AF \u00ae (sotalol HCl). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021151s010lbl.pdf (Accessed 26 April 2021)."},{"key":"e_1_3_4_34_2","unstructured":"TIKOSYN \u00ae (dofetilide) Capsules. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=639 (Accessed 26 April 2021)."},{"key":"e_1_3_4_35_2","unstructured":"Multaq (dronedarone) tablets for oral use. https:\/\/products.sanofi.us\/Multaq\/Multaq.html (Accessed 7 July 2021)."},{"key":"e_1_3_4_36_2","unstructured":"Amiodarone. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/018972s054lbl.pdf (Accessed 7 July 2021)."},{"key":"e_1_3_4_37_2","unstructured":"Drugs.com. Flecainide. https:\/\/www.drugs.com\/pro\/flecainide.html (Accessed 7 July 2021)."},{"key":"e_1_3_4_38_2","unstructured":"Propafenone. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019151s012lbl.pdf (Accessed 7 July 2021)."},{"issue":"5","key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1345\/aph.1L698","article-title":"Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation","volume":"43","author":"Kim MH","year":"2009","unstructured":"Kim MH, Klingman D, Lin J, Pathak P, Battleman DS. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann. Pharmacother. 43(5), 840\u2013848 (2009).","journal-title":"Ann. Pharmacother."},{"key":"e_1_3_4_40_2","unstructured":"KFF. Among Covered Workers With Prescription Drug Coverage Average Copayments and Coinsurance 2021 9805. https:\/\/www.kff.org\/report-section\/ehbs-2021-section-9-prescription-drug-benefits\/attachment\/table-9-6-7\/ (Accessed 15 November 2021)."},{"key":"e_1_3_4_41_2","unstructured":"Multaq dronedarone 400mg Tablets. Start with savings. https:\/\/www.multaq.com\/savings-and-support\/multaq-savings-card-program (Accessed 17 October 2022)."},{"issue":"14","key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial","volume":"143","author":"Packer DL","year":"2021","unstructured":"Packer DL, Piccini JP, Monahan KH Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. Circulation 143(14), 1377\u20131390 (2021).","journal-title":"Circulation"},{"issue":"4","key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCEP.108.824789","article-title":"Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses","volume":"2","author":"Calkins H","year":"2009","unstructured":"Calkins H, Reynolds MR, Spector P Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ. Arrhythm Electrophysiol. 2(4), 349\u2013361 (2009).","journal-title":"Circ. Arrhythm Electrophysiol."},{"issue":"2","key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacep.2016.06.002","article-title":"The Impact of First Procedure Success Rate on the Economics of Atrial Fibrillation Ablation","volume":"3","author":"Mansour M","year":"2017","unstructured":"Mansour M, Karst E, Heist EK The Impact of First Procedure Success Rate on the Economics of Atrial Fibrillation Ablation. JACC Clin. Electrophysiol. 3(2), 129\u2013138 (2017).","journal-title":"JACC Clin. Electrophysiol."},{"key":"e_1_3_4_45_2","first-page":"271","article-title":"Outcomes following catheter ablation of atrial fibrillation in the UK: a single-centre cohort analysis","volume":"17","author":"Gunawardena R","year":"2010","unstructured":"Gunawardena R, Furniss SS, Shepherd E, Santarpia G, Lord SW, Bourke JP. Outcomes following catheter ablation of atrial fibrillation in the UK: a single-centre cohort analysis. Brit. J. Cardiol. 17, 271\u2013276 (2010).","journal-title":"Brit. J. Cardiol."},{"issue":"3","key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/clc.23309","article-title":"Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation\/flutter: insights from the ATHENA study","volume":"43","author":"Vamos M","year":"2020","unstructured":"Vamos M, Calkins H, Kowey PR Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation\/flutter: insights from the ATHENA study. Clin. Cardiol. 43(3), 291\u2013297 (2020).","journal-title":"Clin. Cardiol."},{"issue":"19","key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"European Heart Rhythm A, European Association for Cardio-Thoracic S","year":"2010","unstructured":"European Heart Rhythm A, European Association for Cardio-Thoracic S. Camm AJ, Kirchhof P, Lip GYH Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31(19), 2369\u20132429 (2010).","journal-title":"Eur. Heart J."},{"issue":"2","key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00399-015-0360-z","article-title":"One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care","volume":"26","author":"Goette A","year":"2015","unstructured":"Goette A, Benninger G, Pittrow D, Paar WD, Von Stritzky B, Bosch RF. One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care. Herzschrittmacherther Elektrophysiol. 26(2), 148\u2013154 (2015).","journal-title":"Herzschrittmacherther Elektrophysiol."},{"key":"e_1_3_4_49_2","unstructured":"Sanofi. Dronedarone (Multaq \u00ae ) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation. https:\/\/www.news.sanofi.us\/press-releases?item=118276 (Accessed 3 September 2021)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T12:22:44Z","timestamp":1678796564000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2022-0196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":47,"alternative-id":["10.57264\/cer-2022-0196"],"URL":"https:\/\/doi.org\/10.57264\/cer-2022-0196","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"article-number":"e220196"}}